CencoraWBO:ABC -1.69%69 Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus rates WBO:ABC with a GF Score™ of 69/100 and a GF Value™ of €259.15 (Fairly Valued). The stock has 1 warning sign investors should review. Among 40 Medical Distribution companies, Cencora ranks worse than 2499997.5% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Cencora's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ABC vs CAH, MCK, HSIC: Buyback Yield % Comparison
For the Medical Distribution subindustry, Cencora's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cencora's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora (WBO:ABC) has a Buyback Yield % of 0.00 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cencora and its competitors. Over the past decade, Cencora's Buyback Yield % has ranged from 0.04 to 14.01. According to the industry distribution chart, Cencora ranks #999999 out of 40 companies in the Medical Distribution industry.
Is Cencora's Buyback Yield % too high?
Cencora's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 14.01. Based on the distribution chart, Cencora ranks #999999 out of 40 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cencora has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Buyback Yield % compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #999999 out of 40 companies for Buyback Yield %. This places Cencora in the lower half of its industry. The industry median Buyback Yield % is 0.02. Historically, Cencora's own Buyback Yield % has ranged from 0.04 to 14.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
The median Buyback Yield % among Medical Distribution companies is 0.02, based on 40 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cencora and its competitors. For the Medical Distribution industry, the median Buyback Yield % is 0.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €259.15, compared to a current price of €250.00 — trading 3.5% below its estimated fair value. The current Buyback Yield % is 0.00. Cencora's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be undervalued.
The current stock price of €250.00 is trading 3.5% below its estimated GF Value™ of €259.15.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
Buyback Yield %: 0.00
GF Value™: €259.15 vs. price of €250.00 (3.5% below fair value)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
69GF Score
Get the complete analysis for WBO:ABC
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
